[go: up one dir, main page]

AR125357A2 - Formulaciones y métodos para controlar el ciclo reproductivo y la ovulación - Google Patents

Formulaciones y métodos para controlar el ciclo reproductivo y la ovulación

Info

Publication number
AR125357A2
AR125357A2 ARP220100962A ARP220100962A AR125357A2 AR 125357 A2 AR125357 A2 AR 125357A2 AR P220100962 A ARP220100962 A AR P220100962A AR P220100962 A ARP220100962 A AR P220100962A AR 125357 A2 AR125357 A2 AR 125357A2
Authority
AR
Argentina
Prior art keywords
pharmaceutically acceptable
oil
imwitor
carbopol
formulation
Prior art date
Application number
ARP220100962A
Other languages
English (en)
Inventor
Daniel Roberto Sammartino
Juan Andrs Colman
Original Assignee
Proinvet Innovations S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proinvet Innovations S A filed Critical Proinvet Innovations S A
Publication of AR125357A2 publication Critical patent/AR125357A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Optics & Photonics (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Formulaciones de hormonas, unidades de dosificación que incluyen las formulaciones de hormonas y métodos de uso, relacionados con una formulación de liberación controlada que incluye hormonas, por ejemplo, progesterona. Las formulaciones y métodos son para controlar el ciclo reproductivo y/o la ovulación de un mamífero hembra, por ejemplo, para favorecer la ovulación de un mamífero hembra o sincronizar la ovulación o el celo de un grupo de mamíferos hembra. Además, las formulaciones son para incrementar la probabilidad de que un mamífero hembra quede preñado luego de su inseminación. Reivindicación 1: Una formulación inyectable de liberación controlada, caracterizada porque comprende una o más hormonas; uno o más solventes orgánicos farmacéuticamente aceptables; uno o más ácidos grasos farmacéuticamente aceptables; uno o más tensioactivos farmacéuticamente aceptables; uno o más agentes formadores de gel farmacéuticamente aceptables; y agua; en donde una porción de dichas una o más hormonas se encuentra disuelta en una mezcla que comprende a dichos uno o más solventes orgánicos farmacéuticamente aceptables para formar una porción libre, y una porción de dichas una o más hormonas se encuentra recubierta por dichos uno o más ácidos grasos farmacéuticamente aceptables para formar una porción recubierta, en donde dichas porciones libre y recubierta están comprendidas en una matriz, donde dicha matriz comprende dichos uno o más agentes formadores de geles farmacéuticamente aceptables y dichos uno o más tensioactivos farmacéuticamente aceptables. Reivindicación 6: La formulación de cualquiera de las reivindicaciones 1 a 4, caracterizada porque dichas una o más hormonas se seleccionan del grupo que consiste en uno o más progestágenos naturales o sintéticos, progesterona natural o sintética, un análogo de progesterona, una sal de progesterona, un estrógeno, benzoato de estradiol, cipionato de estradiol, d-cloprostenol sódico, DL cloprostenol sódico, acetato de buserelina y combinaciones de las mismas. Reivindicación 8: La formulación de cualquiera de las reivindicaciones 1 a 4, caracterizada porque dichos uno o más solventes orgánicos farmacéuticamente aceptables se seleccionan del grupo que consiste en etanol, alcohol bencílico, benzoato de bencilo, glicerol, glicerol formal, oleato de etilo, PEG400, propilenglicol, dimetilsulfóxido (DMSO), N-metilpirrolidona, Miglyol, Miglyol 808, Miglyol 810, Miglyol 812, Miglyol 829, Miglyol 8108, Dynacetin 660, Softisan 649, Imwitor491, Imwitor 900 K, Imwitor 900 P, Imwitor 960 K, Imwitor 642, Imwitor 742, Imwitor 928, Imwitor 988, Imwitor 948, Softigen 701 y combinaciones de los mismos. Reivindicación 10: La formulación de cualquiera de las reivindicaciones 2 a 4, caracterizada porque dicho vehículo oleoso farmacéuticamente aceptable se selecciona del grupo que consiste en aceite de lino, aceite de sésamo, aceite de sésamo refinado, aceite de ricino, ácido palmítico, aceite de soja, aceite de soja etoxilado, aceite de girasol, aceite de maíz, aceite de coco, aceite de coco, aceite de oliva, aceite de almendra, aceite de algodón y combinaciones de los mismos. Reivindicación 12: La formulación de cualquiera de las reivindicaciones 1 a 4, caracterizada porque dichos uno o más ácidos grasos farmacéuticamente aceptables se seleccionan del grupo que consiste en cualquier ácido graso saturado o parcialmente insaturado de entre 14 y 22 átomos de carbono. Reivindicación 15: La formulación de cualquiera de las reivindicaciones 2 a 4, caracterizada porque dichos uno o más agentes formadores de estructura farmacéuticamente aceptables se seleccionan del grupo que consiste en celulosa, un derivado de celulosa, celulosa microcristalina, etilcelulosa, hidroxietilcelulosa, hidroxietilmetilcelulosa, hidroxietilpropilcelulosa, carboximetilcelulosa, goma guar, goma arábiga, goma xántica, chitosan, alginato, gelatina, carbopol, Carbopol 71G NF, Carbopol 971P NF, Carbopol 974P NF, Carbopol ETD 2020 NF, Carbopol 5984 ETD, Carbopol Ultrez 10, glicolato sódico de almidón, corscarmelosa sódica, ácido algínico, pectina y combinaciones de los mismos.
ARP220100962A 2015-12-18 2022-04-18 Formulaciones y métodos para controlar el ciclo reproductivo y la ovulación AR125357A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2015/066863 WO2017105512A1 (en) 2015-12-18 2015-12-18 Formulations and methods for controlling the reproductive cycle and ovulation

Publications (1)

Publication Number Publication Date
AR125357A2 true AR125357A2 (es) 2023-07-12

Family

ID=59057228

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP160103873A AR107067A1 (es) 2015-12-18 2016-12-16 Formulaciones y métodos para controlar el ciclo reproductivo y la ovulación
ARP220100962A AR125357A2 (es) 2015-12-18 2022-04-18 Formulaciones y métodos para controlar el ciclo reproductivo y la ovulación

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP160103873A AR107067A1 (es) 2015-12-18 2016-12-16 Formulaciones y métodos para controlar el ciclo reproductivo y la ovulación

Country Status (13)

Country Link
US (1) US10898432B2 (es)
EP (1) EP3389690B1 (es)
CN (1) CN108367046B (es)
AR (2) AR107067A1 (es)
AU (1) AU2016369500A1 (es)
CL (1) CL2018001635A1 (es)
CO (1) CO2018006041A2 (es)
ES (1) ES2893121T3 (es)
MX (1) MX2018007354A (es)
NZ (1) NZ744338A (es)
PE (1) PE20181290A1 (es)
UY (1) UY37033A (es)
WO (2) WO2017105512A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物
WO2017105512A1 (en) 2015-12-18 2017-06-22 Proinvet Innovations S.A. Formulations and methods for controlling the reproductive cycle and ovulation
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
CN111281877A (zh) * 2018-11-22 2020-06-16 南京诺瑞特医药科技有限公司 神经活性类固醇的新制剂
CN110215433A (zh) * 2019-07-16 2019-09-10 苏州素仕生物科技有限公司 一种氯前列醇注射液及其制备方法
WO2021133430A1 (en) * 2019-12-23 2021-07-01 Augusta University Research Institute, Inc. Progesterone formulation to trigger ovulation and provide luteal phase support
CN111346054A (zh) * 2020-03-10 2020-06-30 上海图珐医药科技有限公司 一种黄体酮乳剂型注射剂及其制备方法
CN115137697B (zh) * 2021-08-17 2024-08-23 浙江科瑞特生物科技有限公司 一种d-氯前列醇钠注射液及其制备方法、应用
CN120731079A (zh) * 2023-04-18 2025-09-30 维乐菲尔概念有限公司 用于诱导黄体溶解的组合物和方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599227A (en) 1983-11-07 1986-07-08 Wisconsin Alumni Research Foundation Injectable pharmaceutical preparation for the induction of multiple follicular growth
FR2663223B1 (fr) 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
US20020013304A1 (en) * 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US6028057A (en) 1998-02-19 2000-02-22 Thorn Bioscience, Llc Regulation of estrus and ovulation in gilts
US20030180368A1 (en) * 1998-03-14 2003-09-25 Cenes Drug Delivery Limited Production of microparticles
PT1065936E (pt) * 1998-03-23 2009-09-24 Gen Mills Inc Encapsulação de componentes em produtos comestíveis
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6287588B1 (en) * 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
US20020131988A1 (en) 1999-12-16 2002-09-19 Foster Todd P. Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
AU780182B2 (en) 2000-03-22 2005-03-03 Secretary Of State For Defence, The Pharmaceutical composition for administration to mucosal surfaces
US6589549B2 (en) 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
US6908626B2 (en) 2001-10-12 2005-06-21 Elan Pharma International Ltd. Compositions having a combination of immediate release and controlled release characteristics
WO2003065924A1 (en) 2002-02-08 2003-08-14 Advanced Animal Technology Limited Control of a biological function
US7157102B1 (en) 2002-05-31 2007-01-02 Biotek, Inc. Multi-layered microcapsules and method of preparing same
US20050118206A1 (en) 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle
US20070104778A1 (en) 2005-11-07 2007-05-10 Hongxia Zeng Controlled-release emulsion compositions
NZ595633A (en) 2005-12-02 2013-05-31 Parnell Lab Aust Pty Ltd Increasing pregnancy rates
CA2648280C (en) * 2006-04-03 2014-03-11 Isa Odidi Controlled release delivery device comprising an organosol coat
US20100098735A1 (en) * 2006-10-05 2010-04-22 Rajesh Jain Injectable depot compositions and its process of preparation
MXPA06015172A (es) 2006-12-20 2009-04-17 Gonzalo Urbiola Verdejo Solucion inyectable de progesterona de liberacion prolongada para uso veterinario y proceso de obtencion del mismo.
CN101152186B (zh) 2007-09-05 2011-07-06 杭州平和安康医药科技有限公司 黄体酮注射液及其制备方法
CN101427993A (zh) * 2008-11-20 2009-05-13 沈阳万爱普利德医药科技有限公司 前列腺素微乳凝胶制剂及其制备方法
CN102291992A (zh) 2009-01-26 2011-12-21 哈尔·维特 同期发情制剂和有效的无cidr方案
WO2010117873A2 (en) * 2009-04-06 2010-10-14 Banner Pharmacaps, Inc. Progesterone solutions for increased bioavailability
UY33103A (es) 2009-12-15 2011-07-29 Techsphere S A De C V Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico
CN101856361A (zh) 2010-06-08 2010-10-13 瓜州县龙兴畜牧产业发展有限公司 一种用于母牛发情调控的孕酮复合制剂
US9375437B2 (en) 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
AR082266A1 (es) 2011-05-13 2012-11-28 Univ Nac Del Litoral Microparticula inyectable de liberacion controlada
US8951996B2 (en) * 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
CN103284955A (zh) 2012-03-02 2013-09-11 上海市计划生育科学研究所 长效孕激素缓释注射埋植剂及其制备方法
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
JP6397402B2 (ja) * 2012-06-18 2018-09-26 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 膣内挿入用可溶性エストラジオールカプセル
CN103585103A (zh) 2012-08-15 2014-02-19 杭州伟智生物医药科技有限公司 一种含tpgs的性激素微纳米人体注射乳剂及其制备方法
US20150297733A1 (en) * 2012-11-14 2015-10-22 Trimel Biopharma Srl Controlled release topical testosterone formulations and methods
WO2017105512A1 (en) 2015-12-18 2017-06-22 Proinvet Innovations S.A. Formulations and methods for controlling the reproductive cycle and ovulation

Also Published As

Publication number Publication date
NZ744338A (en) 2020-03-27
CN108367046A (zh) 2018-08-03
BR112017018319A2 (pt) 2018-04-17
AR107067A1 (es) 2018-03-14
CO2018006041A2 (es) 2018-07-10
US20180289614A1 (en) 2018-10-11
US10898432B2 (en) 2021-01-26
WO2017106618A1 (en) 2017-06-22
CL2018001635A1 (es) 2018-08-17
UY37033A (es) 2017-07-31
AU2016369500A1 (en) 2018-06-07
MX2018007354A (es) 2018-11-09
ES2893121T3 (es) 2022-02-08
EP3389690A4 (en) 2019-08-28
EP3389690A1 (en) 2018-10-24
WO2017105512A1 (en) 2017-06-22
CN108367046B (zh) 2021-12-21
PE20181290A1 (es) 2018-08-07
EP3389690B1 (en) 2021-07-07

Similar Documents

Publication Publication Date Title
AR125357A2 (es) Formulaciones y métodos para controlar el ciclo reproductivo y la ovulación
AU2019204653B2 (en) Soluble Estradiol Capsule For Vaginal Insertion
RU2215520C2 (ru) Гормональная композиция для местного нанесения с системным действием
RU2019142696A (ru) Естественная комбинация составов и способов гормонозаместительной терапии
RU2000126490A (ru) Гормональная композиция для местного нанесения с системным действием
RU2012121708A (ru) Трансдермальные фармацевтические композиции, содержащие активные агенты
CL2013003163A1 (es) Composición transdermica de ibuprofeno, util en el tratamiento del dolor o la inflamacion.
RU2010114233A (ru) Применение гидрофобин-полипептидов в качестве усилителя пенетрации
ECSP055574A (es) Uso de derivados de tio-oxindol en el tratamiento de condiciones relacionadas con hormonas.
ES8500738A1 (es) Un procedimiento para la preparacion de una composicion antiinflamatoria topica como unguento en forma de gel
RU2008130890A (ru) Композиции, аппликаторы, наборы с конъюгированным эстрогеном и способы их получения и применения
ES2323082T5 (es) Agente formador de oleogeles, que contiene triterpenos, un oleogel que contiene triterpenos y procedimiento para la producción de un oleogel que contiene triterpenos.
WO2005025488A3 (en) Methods for the controlled delivery of pharmacologically active compounds
GOSWAMI et al. Uterine lipid metabolism in mice during the oestrous cycle: effect of ovariectomy and replacement therapy
CU20100008A7 (es) Estratrienos 8-beta sustituidos como estrógenos de acción selectiva
Johnson Ovarian androgens in parabiotic rats
CN211213286U (zh) 一种妇产科临床手术用阴部扩撑器
McAllan Reproductive endocrinology of prototherians and metatherians
UY26665A1 (es) Estratrienos sustituidos como estrógenos selectivamente activos
GB490942A (en) Process for the manufacture of highly concentrated solutions of fat soluble hormones and derivatives thereof
US9713621B2 (en) Treatment of endometriosis
NZ622985A (en) Stabilized vitamin d formulations
PE20020752A1 (es) Esteroides con doble enlace delta 14 sustituido en las posiciones 13 y 14 con actividad androgenica y progestagena
Calka et al. Study of chemical coding of the CSMG neurons supplying prepyloric region of the porcine stomach following acetylsalicylic acid supplementation and after partial stomach resection
GB617419A (en) Improvements relating to therapeutic preparation and methods of preparing the same